ADT and risk for diagnosis with dementia? “Not in the UK”, they say!

Just a few weeks ago we reported data from a study in California suggesting an association between treatment with androgen deprivation therapy (ADT) for prostate cancer and subsequent risk for diagnosis with dementia or Alzheimer’s disease. … READ MORE …

ADT + sipuleucel-T in treatment of hormone-sensitive prostate cancer

One of the major unanswered questions at this time is whether immunotherapy of some type, if given early to patients with prostate cancer, can help to lower risk of progression of the disease. … READ MORE …

Early data from the PATCH trial in the UK

Since 2007 a randomized clinical trial in the UK (the so-called PATCH trial) has been comparing the effectiveness and safety of transdermal estradiol patches to implants of an LHRH receptor agonist (goserelin acetate) in the treatment of advanced prostate cancer. … READ MORE …

Does ADT increase risk for all types of dementia?

Back in December last year, a group of researchers suggested that androgen deprivation therapy (ADT) might be associated with increased risk for Alzheimer’s disease (see “Is ADT giving you Alheimer’s disease?“) … READ MORE …

After long-term ADT … recovery of normal hormonal function?

A group of Spanish clinical researchers have reported recent data from a small study designed to address an unanswered question about the recovery of (relatively) normal hormonal function after completion of androgen deprivation therapy (ADT). … READ MORE …

Does long-term ADT really affect cognitive function or not?

After > 50 years of use of various forms of androgen deprivation therapy (ADT), we still don’t really have a clear idea of whether or the degree to which long-term, continuous ADT can affect cognitive function — although there is no doubt at all that many patients believe it does. … READ MORE …

Mutation to inherited HSD3B1 gene associated with more aggressive form of prostate cancer

According to an article to appear in the September issue of The Lancet Oncology, some patients with aggressive prostate cancer are more likely to die earlier from their disease if they carry a specific testosterone-related genetic abnormality. … READ MORE …